Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...
(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...
Our insulin franchise, more specifically Lantus is very resilient and sales ... This transaction marks an important strategic step for Sanofi to become a pure-play and science-focused biopharma ...
Sanofi SNY reported third-quarter 2024 adjusted ... driven mainly by higher sales in United States and China. Lantus sales rose 33.8% to €431.0 million. Plavix sales increased 8.3% to €230 ...
Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...
Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...
Agomab Therapeutics is benefiting from Sanofi’s push to become an immunology powerhouse.
(Reuters) - French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.
Sanofi's wide lineup of branded drugs and vaccines ... launches offsetting patent losses and deteriorating pricing for Lantus. Following a sharp patent cliff in 2013, Sanofi faces relatively ...
Sanofi SNY reported third-quarter 2024 adjusted earnings of $1.57 per American depositary share, which beat the Zacks Consensus Estimate of $1.35 per share. Earnings of €2.86 per share rose 12.2 ...
Sanofi reported a 25% boost in sales for its vaccines division during the third quarter, helped by earlier-than-anticipated orders of its flu shots as well as rising revenue from Beyfortus, its RSV ...
Leerink Partners analyst David Risinger in a Friday note to investors said Sanofi expects Q4 Beyfortus sales similar to Q3. Sanofi released its third-quarter earnings report on Friday, beating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback